Cybin (HELP) Short term Debt (2021)

Cybin (HELP) reported Short term Debt of $2.4 million for Q4 2021, up 730.83% quarter-over-quarter from $288370.6 in Q3 2021.

Cybin (HELP) Short term Debt (2021) Analysis & Trends

Cybin has reported Short term Debt for 1 years, with the latest figure at $2.4 million in Q4 2021.

For the quarter ending Q4 2021, Short term Debt changed N/A year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2021 stood at $2.4 million (changed N/A YoY), and the FY2021 full-year result was $864368.4, changed N/A from the prior year.
Short term Debt for Q4 2021 stood at $2.4 million, up from $288370.6 in the prior quarter.
The five-year high for Short term Debt was $2.4 million in Q4 2021, with the low at $288370.6 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Cybin	75.42 Mn	75.42 Mn	-

Download Data